+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID06282575

Open-label Randomized Study Comparing Zanidatamab Plus Standard Chemotherapy With or Without PD-1L1 Inhibitors Versus Standard Chemotherapy Alone for Advanced HER2-positive Biliary Tract Cancer

Led by Jazz Pharmaceuticals · Updated on 2026-10-28

286

Participants Needed

185

Research Sites

69 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the use of Zanidatamab combined with standard chemotherapy drugs Cisplatin and Gemcitabine, with or without an additional immune therapy drug chosen by the doctor, for adults with HER2-positive biliary tract cancer. This study aims to assess the effectiveness and safety of adding Zanidatamab to the current standard treatment for this advanced cancer type. Participants will be randomly assigned to receive either Zanidatamab plus Cisplatin and Gemcitabine with or without a PD-1L1 inhibitor either Durvalumab or Pembrolizumab or the standard treatment of Cisplatin and Gemcitabine with or without the same immune therapy drugs. All medications are given through intravenous infusions. The study treatment continues under medical supervision and may vary according to local drug approvals. During the trial, participants will have regular assessments including tumor evaluations to measure progression-free survival and overall survival, along with monitoring treatment response and side effects. Patient-reported outcomes on physical functioning and symptom severity will also be collected. The study may last up to several years, with continuous safety monitoring and follow-up visits to evaluate long-term effects and treatment impact.

CONDITIONS

Brief Title

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

Research Team

C

Clinical Trial Disclosure & Transparency

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here